Logo wahanariau.com
  2. Teva pharmaceutical

Teva pharmaceutical

Index
Globenewswire

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

Selasa, 08 Oktober 2024 - 18:30:00 Wib
Globenewswire

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

Kamis, 03 Oktober 2024 - 20:00:00 Wib
Globenewswire

Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024

Selasa, 01 Oktober 2024 - 18:31:45 Wib
Globenewswire

Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia

Senin, 23 September 2024 - 12:30:00 Wib
Globenewswire

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia

Sabtu, 21 September 2024 - 16:00:00 Wib
Globenewswire

Teva to Present at the Bank of America 2024 Global Healthcare Conference

Kamis, 12 September 2024 - 06:01:11 Wib
Globenewswire

Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Selasa, 27 Agustus 2024 - 05:55:33 Wib
Globenewswire

Teva Announces Strong Growth in Second Quarter Revenues Mainly Driven by Generics Products in All Regions and AUSTEDO®; Raises 2024 Financial Guidance

Rabu, 31 Juli 2024 - 18:30:00 Wib